Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors

Simple item page
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorAvcı, Nilüfer
dc.contributor.buuauthorCanhoroz, Mustafa
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorManavoǧlu, Osman
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.scopusid53986153800tr_TR
dc.contributor.scopusid26435400000tr_TR
dc.contributor.scopusid55390409800tr_TR
dc.contributor.scopusid52663246200tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.date.accessioned2022-01-19T12:22:50Z
dc.date.available2022-01-19T12:22:50Z
dc.date.issued2012
dc.description.abstractPurpose: Gastrointestinal stromal tumors (GISTs) have a complex biology which is reflected by a marked clinical heterogeneity. Thus, there has been great interest in identifying prognostic factors influencing tumor recurrence and survival. The aim of this study was to identify potential clinical and immunohistochemical prognostic factors that may affect survival and treatment outcomes inpatients with metastatic GISTs. Methods: Between 2000 and September 2011, a total of 41 patients with metastatic GISTs (29 males and 12 females; mean age: 57.4 +/- 11.8 years; range 29-74) were referred to the Department of Oncology, Uludag University Medical School. Survival analysis for a number of potential prognostic factors was made with the main outcome results of progression-free survival (PFS) and overall survival (OS). Results: The most common sites of isolated metastases comprised the liver (n=18), followed by lymph nodes (n=5), the omentum (n=1), and the mesothelium (n=1). The remaining patients had metastases at multiple sites. Cox regression analysis identified ileal location as the only significant predictor of poor PFS both after first-line (p=0.023) and second-line therapy (p=0.016). Tumor location in the ileum (p=0.025) and S100 immunoreactivity (p=0.041) were both independent predictors of OS. Conclusion: Tumor site and S100 positivity were the main significant independent predictors of clinical outcomes in patients with metastatic GISTs treated by standard of care.en_US
dc.identifier.citationÇubukçu, E. vd. (2012). "Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors". Journal of BUON, 17(3), 517-521.en_US
dc.identifier.endpage521tr_TR
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3tr_TR
dc.identifier.pubmed23033292tr_TR
dc.identifier.scopus2-s2.0-84867492647tr_TR
dc.identifier.startpage517tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/24169
dc.identifier.volume17tr_TR
dc.identifier.wos000309793000018tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.journalJournal of BUONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectGastrointestinal stromal tumorsen_US
dc.subjectPrognosisen_US
dc.subjectS100 markeren_US
dc.subjectTumor locationen_US
dc.subjectDifferential-diagnosisen_US
dc.subjectMolecular pathologyen_US
dc.subjectDifferent sitesen_US
dc.subjectS100 proteinsen_US
dc.subjectGisten_US
dc.subjectMorphologyen_US
dc.subjectConsensusen_US
dc.subjectSurvivalen_US
dc.subjectCanceren_US
dc.subject.emtreeImatiniben_US
dc.subject.emtreeProtein s 100en_US
dc.subject.emtreeSunitiniben_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer prognosisen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical assessmenten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGastrointestinal stromal tumoren_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImmunohistochemistryen_US
dc.subject.emtreeImmunoreactivityen_US
dc.subject.emtreeLeg edemaen_US
dc.subject.emtreeLiver metastasisen_US
dc.subject.emtreeLymph node metastasisen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMesotheliumen_US
dc.subject.emtreeOmentumen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreeProportional hazards modelen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshFemaleen_US
dc.subject.meshGastrointestinal neoplasmsen_US
dc.subject.meshGastrointestinal stromal tumorsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNeoplasm metastasisen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProportional hazards modelsen_US
dc.subject.meshS100 proteinsen_US
dc.subject.scopusGastrointestinal Stromal Tumors; Imatinib; Sunitiniben_US
dc.subject.wosOncologyen_US
dc.titleIdentification of prognostic factors in patients with metastatic gastrointestinal stromal tumorsen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Collections

Web of Science
Scopus